(IPN) Ipsen - Ratings and Ratios
Oncology, Neuroscience, Rare Disease, Biopharma
Dividends
| Dividend Yield | 1.14% |
| Yield on Cost 5y | 2.19% |
| Yield CAGR 5y | 4.66% |
| Payout Consistency | 97.2% |
| Payout Ratio | 26.1% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 23.4% |
| Value at Risk 5%th | 37.8% |
| Relative Tail Risk | -2.08% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.43 |
| Alpha | 9.22 |
| CAGR/Max DD | 0.28 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.464 |
| Beta | 0.017 |
| Beta Downside | 0.239 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.25% |
| Mean DD | 10.88% |
| Median DD | 11.47% |
Description: IPN Ipsen November 03, 2025
Ipsen S.A. (ticker IPN) is a French-based, globally-active biopharmaceutical firm that concentrates on three therapeutic areas: oncology, neuroscience, and rare diseases. The company’s product portfolio includes marketed assets such as Somatuline, Cabometyx, Dysport, and Bylvay, complemented by a pipeline of late-stage candidates.
Key late-stage programs comprise Cabometyx + Atezolizumab (Phase III for second-line metastatic castration-resistant prostate cancer), Tazverik (Phase III for second-line follicular lymphoma), Bylvay (Phase III for biliary atresia), and Dysport (Phase III for chronic and episodic migraine). Earlier-stage assets include Fidrisertib (Phase II for fibrodysplasia ossificans progressiva), Elafibranor (Phase II for primary sclerosing cholangitis), and several IPN-coded molecules targeting neurotoxin aesthetics, multiple myeloma, and viral cholestatic disease.
In 2023 Ipsen reported revenue of approximately €2.2 billion, with R&D expenditures representing roughly 27 % of sales-a level that exceeds the GICS pharmaceutical average of ~20 % and reflects the company’s heavy pipeline investment. The firm’s net debt stood at €1.1 billion, giving a net-debt-to-EBITDA ratio of about 2.2×, which is modest relative to peers that often trade above 3×. Growth drivers for the sector include an aging global population (projected to increase demand for oncology and rare-disease therapies by 15 % over the next five years) and accelerating regulatory pathways for accelerated approvals, which can shorten time-to-market for late-stage candidates.
For a deeper quantitative assessment of IPN’s valuation and risk profile, consider exploring the analytics available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (1.13b TTM) > 0 and > 6% of Revenue (6% = 419.1m TTM) |
| FCFTA 0.23 (>2.0%) and ΔFCFTA 6.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 19.98% (prev 8.28%; Δ 11.70pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.27 (>3.0%) and CFO 1.88b > Net Income 1.13b (YES >=105%, WARN >=100%) |
| Net Debt (-483.2m) to EBITDA (2.50b) ratio: -0.19 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (83.5m) change vs 12m ago -0.01% (target <= -2.0% for YES) |
| Gross Margin 82.18% (prev 83.07%; Δ -0.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 106.2% (prev 51.90%; Δ 54.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 35.84 (EBITDA TTM 2.50b / Interest Expense TTM 50.0m) >= 6 (WARN >= 3) |
Altman Z'' 8.56
| (A) 0.20 = (Total Current Assets 2.81b - Total Current Liabilities 1.42b) / Total Assets 6.83b |
| (B) 0.61 = Retained Earnings (Balance) 4.19b / Total Assets 6.83b |
| (C) 0.27 = EBIT TTM 1.79b / Avg Total Assets 6.58b |
| (D) 3.23 = Book Value of Equity 8.39b / Total Liabilities 2.60b |
| Total Rating: 8.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.42
| 1. Piotroski 7.50pt |
| 2. FCF Yield 15.62% |
| 3. FCF Margin 22.54% |
| 4. Debt/Equity 0.23 |
| 5. Debt/Ebitda -0.19 |
| 6. ROIC - WACC (= 24.27)% |
| 7. RoE 27.74% |
| 8. Rev. Trend 75.06% |
| 9. EPS Trend -22.56% |
What is the price of IPN shares?
Over the past week, the price has changed by -1.53%, over one month by -1.37%, over three months by +2.09% and over the past year by +12.47%.
Is IPN a buy, sell or hold?
What are the forecasts/targets for the IPN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 130.4 | 6.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 131.5 | 7.5% |
IPN Fundamental Data Overview November 27, 2025
Market Cap EUR = 10.57b (10.57b EUR * 1.0 EUR.EUR)
P/E Trailing = 23.8548
P/E Forward = 12.0773
P/S = 2.8106
P/B = 2.4884
P/EG = 0.6846
Beta = 0.143
Revenue TTM = 6.99b EUR
EBIT TTM = 1.79b EUR
EBITDA TTM = 2.50b EUR
Long Term Debt = 745.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 123.7m EUR (from shortTermDebt, last quarter)
Debt = 961.8m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -483.2m EUR (from netDebt column, last quarter)
Enterprise Value = 10.08b EUR (10.57b + Debt 961.8m - CCE 1.45b)
Interest Coverage Ratio = 35.84 (Ebit TTM 1.79b / Interest Expense TTM 50.0m)
FCF Yield = 15.62% (FCF TTM 1.57b / Enterprise Value 10.08b)
FCF Margin = 22.54% (FCF TTM 1.57b / Revenue TTM 6.99b)
Net Margin = 16.16% (Net Income TTM 1.13b / Revenue TTM 6.99b)
Gross Margin = 82.18% ((Revenue TTM 6.99b - Cost of Revenue TTM 1.25b) / Revenue TTM)
Gross Margin QoQ = 82.14% (prev 83.43%)
Tobins Q-Ratio = 1.48 (Enterprise Value 10.08b / Total Assets 6.83b)
Interest Expense / Debt = 1.63% (Interest Expense 15.7m / Debt 961.8m)
Taxrate = 21.06% (89.5m / 425.0m)
NOPAT = 1.41b (EBIT 1.79b * (1 - 21.06%))
Current Ratio = 1.98 (Total Current Assets 2.81b / Total Current Liabilities 1.42b)
Debt / Equity = 0.23 (Debt 961.8m / totalStockholderEquity, last quarter 4.23b)
Debt / EBITDA = -0.19 (Net Debt -483.2m / EBITDA 2.50b)
Debt / FCF = -0.31 (Net Debt -483.2m / FCF TTM 1.57b)
Total Stockholder Equity = 4.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.53% (Net Income 1.13b / Total Assets 6.83b)
RoE = 27.74% (Net Income TTM 1.13b / Total Stockholder Equity 4.07b)
RoCE = 37.21% (EBIT 1.79b / Capital Employed (Equity 4.07b + L.T.Debt 745.6m))
RoIC = 29.95% (NOPAT 1.41b / Invested Capital 4.72b)
WACC = 5.68% (E(10.57b)/V(11.53b) * Re(6.08%) + D(961.8m)/V(11.53b) * Rd(1.63%) * (1-Tc(0.21)))
Discount Rate = 6.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.01%
[DCF Debug] Terminal Value 79.97% ; FCFE base≈1.37b ; Y1≈1.55b ; Y5≈2.10b
Fair Price DCF = 441.4 (DCF Value 36.41b / Shares Outstanding 82.5m; 5y FCF grow 15.13% → 3.0% )
EPS Correlation: -22.56 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 75.06 | Revenue CAGR: 55.75% | SUE: 1.09 | # QB: 1
EPS next Year (2026-12-31): EPS=11.21 | Chg30d=-0.013 | Revisions Net=+2 | Growth EPS=-5.3% | Growth Revenue=+3.2%